Bull Harbor Capital LLC Takes Position in Illumina, Inc. $ILMN

Bull Harbor Capital LLC acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 11,461 shares of the life sciences company’s stock, valued at approximately $1,413,000.

Several other institutional investors have also modified their holdings of the company. Capital World Investors increased its holdings in Illumina by 0.6% in the fourth quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock valued at $2,636,483,000 after buying an additional 124,323 shares during the last quarter. State Street Corp lifted its holdings in Illumina by 3.2% during the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock worth $811,895,000 after buying an additional 190,324 shares during the last quarter. WCM Investment Management LLC lifted its holdings in Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after buying an additional 1,851,848 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Illumina by 30.3% during the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after buying an additional 1,028,099 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Illumina by 4.8% during the 4th quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock worth $375,260,000 after acquiring an additional 130,139 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Trading Up 1.0%

NASDAQ:ILMN opened at $194.82 on Thursday. The firm has a market cap of $29.48 billion, a P/E ratio of 35.42, a PEG ratio of 2.85 and a beta of 1.47. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The stock’s 50 day simple moving average is $174.28 and its 200-day simple moving average is $146.38. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $199.14.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the business earned $0.97 earnings per share. The company’s quarterly revenue was up 4.8% compared to the same quarter last year. Equities analysts anticipate that Illumina, Inc. will post 5.22 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on ILMN shares. Royal Bank Of Canada initiated coverage on Illumina in a report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price objective on the stock. Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research note on Thursday, May 14th. Citigroup upped their price target on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a report on Monday, May 4th. Evercore reiterated an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Finally, Canaccord Genuity Group raised their price objective on shares of Illumina from $140.00 to $190.00 and gave the stock a “hold” rating in a report on Tuesday, July 14th. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $156.88.

Insider Buying and Selling

In other Illumina news, SVP Christensen Jakob Wedel sold 700 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the transaction, the senior vice president directly owned 15,056 shares of the company’s stock, valued at approximately $2,093,386.24. The trade was a 4.44% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 1,500 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total transaction of $225,150.00. Following the completion of the sale, the chief accounting officer owned 14,946 shares of the company’s stock, valued at $2,243,394.60. This trade represents a 9.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,003,769 shares of company stock worth $155,710,908 in the last ninety days. Insiders own 2.90% of the company’s stock.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.